Market Overview

Spectrum Pharma Down 6% After Missing Earnings Estimates

Spectrum Pharma (NASDAQ: SPPI) is down 6% after the company missed earnings estimates this morning.

The Company recorded net income of $49 million, or $0.91 per basic and $0.84 per diluted share in the twelve month period ended December 31, 2011, compared to a net loss of $49 million, or ($0.99) per basic and diluted share in 2010. Total research and development expenses were $28 million in 2011, as compared to $57 million in 2010, which included the $30 million up-front licensing fee for belinostat. Selling, general and administrative expenses were $73 million in 2011, which included non-cash charges of $21 million, compared to $49 million in 2010, which included non-cash charges of $6 million.

During the twelve-month period ended December 31, 2011, net cash provided by operations was approximately $43 million. Cash, equivalents, investments and receivables as of December 31, 2011 aggregated $222 million, as compared to $125 million as of December 31, 2010.

Posted-In: Earnings News Intraday Update Movers

 

Related Articles (SPPI)

Around the Web, We're Loving...

Get Benzinga's Newsletters